Age-related decline in immunity is a dominant driver of shingles, and almost all your patients aged 50 and over are at risk.* 1 – 3 If your patients currently have, or develop, certain medical conditions, their risk of shingles could increase further. 4 – 6
Compared with controls without the condition † 4
For Australian Healthcare professionals
THIS SHINGLES ACTION WEEK, MAKE THE CONVERSATION PERSONAL TOO
Age-related decline in immunity is a dominant driver of shingles, and almost all your patients aged 50 and over are at risk.* 1 – 3 If your patients currently have, or develop, certain medical conditions, their risk of shingles could increase further. 4 – 6
Compared with controls without the condition † 4
DIABETES |
+ 24 % RISK
RR 1.24( 95 % CI 1.14, 1.35) 32 studies
|
CHRONIC RENAL DISEASE |
RR 1.29( 95 % CI 1.10, 1.51) 18 studies |
CV
CONDITIONS ‡
|
RR 1.34( 95 % CI 1.17, 1.54) 16 studies |
Absolute risk, patient numbers and patient age range for individual conditions not reported. 4
‡
Cardiovascular conditions included varied by study: RR by specific cardiovascular conditions not reported and may not be significant. 4, 7
Talk to your patients aged ≥50 years about the factors contributing to their shingles risk
CI, confidence interval; CV, cardiovascular; RR, risk ratio. * Includes US data. May not be representative of the Australian population.
†
Selected risk factors from systematic literature review( 1966 – 2019) of observational studies and meta-analysis of 18 risk factors. 4
References: 1. Centers for Disease Control and Prevention. MMWR. 2008 June; 57( RR-5): 1 – 30. 2. Australian Technical Advisory Group on Immunisation( ATAGI). Australian Immunisation Handbook. Zoster( herpes zoster) [ updated 2025 Feb 7; accessed 2025 Feb 13 ]. Available at: immunisationhandbook. health. gov. au. 3. National Centre for Immunisation Research and Surveillance( NCIRS). Zoster( shingles) vaccine: frequently asked questions( FAQs) [ updated 2025 Feb 14; accessed 2025 Mar 5 ]. Available at: ncirs. org. au / zoster-shingles / zoster-shingles-vaccine-frequently-asked-questions-faqs. 4. Marra F et al. Open Forum Infec Dis 2020; 7: ofaa005. 5. Kawai K et al. Mayo Clin Proc 2017; 92:1806 – 21. 6. Steinmann M et al. Infection 2024; 52:1009 – 26. 7. Marra F et al. Open Forum Infec Dis 2020; 7: ofaa005( Supplementary data).
This disease awareness program is sponsored by GlaxoSmithKline Australia Pty Ltd. Melbourne, VIC. ABN 47 100 162 481. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trade marks are owned by or licensed to the GSK group of companies. © 2026 GSK group of companies or its licensor. NP-AU-HZU-JRNA-260001. Date of approval: January 2026.